医
China Med Service
Best doctors, yours
Breaking down language, channel and process barriers in cross-border care — making the best doctors your personal doctors.
300 Grade-A partner hospitals · 3,000+ leading experts · one-stop service across all specialties
Other hypoparathyroidism (E20.800) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Pseudohypoparathyroidism (E20.100x002) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Pseudohypoparathyroidism (Albright hereditary osteodystrophy) is end-organ PTH resistance with hypocalcemia/hyperphosphatemia despite high PTH; short stature, round face, short 4th/5th metacarpals; subcutaneous calcification.
内分泌科Primary hypoparathyroidism (E20.000x012) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Primary hypoparathyroidism (E20.000x003) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Idiopathic hypoparathyroidism (E20.000x001) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Idiopathic hypoparathyroidism (E20.000) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Islet-cell hyperplasia (E16.901) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Pancreatic endocrine-cell hyperplasia (E16.900x002) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being co
Pancreatic endocrine disorder (E16.900) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Metabolic syndrome is cluster of abdominal obesity, hypertension, dyslipidemia (high triglycerides, low HDL), hyperglycemia/insulin resistance; doubled cardiovascular and type-2-diabetes risk; lifestyle + pharmacologic management.
内分泌科Increased pancreatic somatostatin (E16.802) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Insulin resistance (E16.801) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Impaired glucose tolerance (E16.800x901) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being compiled.
Impaired glucose tolerance with acanthosis/dyslipidemia/hyperinsulinemia/obesity (E16.800x105) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a det
Impaired glucose tolerance with insulin resistance (E16.800x104) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introductio
Impaired glucose tolerance with increased visceral-fat deposition (E16.800x103) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathologi
Impaired glucose tolerance with hypertension (E16.800x102) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is b
Impaired glucose tolerance with obesity hypertension (E16.800x101) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduct
Autoimmune insulin-receptor disease (E16.800x041) is a disease entity listed in the National Clinical Version 2.0 of the Disease Classification and Codes standard issued by the National Health Commission; a detailed pathological introduction is being comp
|
